Which placebo to cure depression? A thought-provoking network meta-analysis

Area of Science:

• Psychiatry
• Clinical Psychology
• Evidence-Based Medicine

Background:

• Antidepressants are often debated as being no more effective than placebos.
• Meta-analyses can rank antidepressants, suggesting placebo effects might also be rankable.
• This study explores if placebo effects differ across various clinical trial contexts.

Purpose of the Study:

• To investigate the epistemological question of whether placebo effects differ across different clinical situations in major depressive disorder trials.
• To compare the efficacy of different placebos indirectly using network meta-analysis.

Main Methods:

• A systematic literature search was conducted across multiple databases for randomized controlled trials (RCTs) involving fluoxetine, venlafaxine, and their placebos.
• Network meta-analyses were performed to compare response and remission rates for three types of placebos.
• Publication bias was assessed using funnel plots and statistical testing.

Main Results:

• No significant differences were found in response or remission rates among the three types of placebos.
• Antidepressant medications demonstrated significantly greater efficacy than placebos.
• Venlafaxine was found to be more efficacious than fluoxetine.
• A significant publication bias was detected in the funnel plots.

Conclusions:

• The presence of publication bias raises uncertainty about the comparability of placebos (sucrose) across major depressive disorder trials.
• Clinicians should maintain an objective perspective when interpreting scientific findings.
• Understanding placebo effects is crucial for clinical practice, potentially more so than ranking antidepressant efficacy.